Biopharmaceuticals produced through bioprocessing are emerging as next generation sources beyond semiconductors in Korea. The large companies in Korea such as Samsung, SK and LG are attracting attention to Bio, and the portion of biopharmaceuticals is rapidly increasing in the global pharmaceutical market, and its proportion is expected to reach 27% of the pharmaceutical market at 2020.
What are some of these Bio drugs? I will examine the patentability of the subject after considering the subject from the viewpoint of invention and patent. First, if you classify drugs, you can divide them into chemically synthesized drugs and biopharmaceuticals depending on the molecule type. Biopharmaceuticals can be defined as high-molecular-weight drugs that use raw materials derived from organisms and produce by biological processes such as cell culture. These include recombinant protein drugs such as insulin, antibody drugs used as anticancer drugs, vaccines, cell therapy, gene therapy, tissue culture, tissue isolated from blood, and allergens used for the treatment of allergies.
In this seminar, I will look at the necessity of protection of biotechnology patents in general and the direction of protection, especially the recent issues related to biopharmaceuticals. We will examine the patentability of invention, patentability, patent requirements of each invention, and the protection of appropriate rights by understanding these patent systems.
We will also look at global patent protection and IP protection strategies for the global business of biopharmaceuticals. I will analyze the patent strategy of a biopharmaceutical company that has infinite competition in the global market based on the published information, compare it with our IP strategy and think about the effective IP strategy of our situation

• Hye Ri Lee(Jungjin International Intellectual Property law Firm)